India Merger Acquisition MCA Regulatory Filings — August 08, 2026

08-08-2026

Oxford Industries Ltd. reported a net loss of ₹3.45 Lakh for the quarter ended June 30, 2026, compared to a profit of ₹28.08 Lakh in the same quarter last year, driven by zero revenue and a reliance on other income which also fell to nil. The Board approved a 99% reduction of share capital to offset accumulated losses of ₹12,95,40,119, and accepted the resignation of Mrs. Kattakota Satyabati Devi as Whole Time Director, redesignating her as Non-Executive Director. The company also deferred a proposal to shift its registered office to another state.

• · The company had zero revenue from operations in both Q1 FY27 and Q1 FY26.
• · Other income dropped from ₹32.55 Lakh in Q1 FY26 to nil in Q1 FY27.
• · Total expenses decreased marginally from ₹4.47 Lakh to ₹3.45 Lakh.
• · The Board approved a 99% reduction of share capital to offset accumulated losses of ₹12,95,40,119 as of March 31, 2026.
• · Post-reduction, paid-up capital will be ₹5,93,600 (59,360 shares of ₹10 each).
• · Mrs. Kattakota Satyabati Devi resigned as Whole Time Director effective August 8, 2026, and was redesignated as Non-Executive Director.
• · The proposal to shift the registered office to another state was deferred.
• · The 45th Annual General Meeting is scheduled for September 11, 2026, via video conferencing.
• · The Register of Members will be closed from September 5 to September 11, 2026.
• · Mr. Saroj Kumar Choudhury is the new promoter, holding 27,61,576 shares (46.46%).

08-08-2026

RDB Infrastructure and Power Limited has acquired a 49% partnership interest in M/s Arankam Green Energy Solution for ₹90,00,000 (Rupees Ninety Lakhs) to develop a 6.3 MW solar plant in Uttar Pradesh. The remaining 51% interest will be acquired after one year from the Commercial Operation Date. The acquisition is a cash transaction and the firm will become a related party post-execution.

• · The acquisition was completed on 8th August 2026 via execution of a Reconstituted Partnership Deed.
• · Registration with the Registrar of Firms (RoF) is a post-completion statutory formality.
• · The firm was incorporated on 20th April 2025 and has no turnover for the last 3 years.
• · The acquisition does not fall within related party transactions at execution time but the firm will become a related party thereafter.
• · No governmental or regulatory approvals were required for the acquisition.

08-08-2026

Chemkart India Limited has made a further investment of Rs. 1.00 Crore in its wholly owned subsidiary, Easy Raw Materials Private Limited, through a rights issue, allotting 10,00,000 equity shares at Rs. 10 each. The investment is part of the IPO proceeds utilization for commissioning the subsidiary's manufacturing unit. The subsidiary has reported nil turnover for the last three years and a loss after tax of Rs. 59.47 Lakh as of March 31, 2026, though its net worth stands at Rs. 578.60 Lakh.

• · Authorized share capital of subsidiary is Rs. 10,00,00,000 (Rupees Ten Crores) divided into 1,00,00,000 equity shares of Rs. 10 each.
• · Paid-up share capital post allotment is Rs. 8,51,00,000 (Rupees Seven Crores Fifty-One Lakh) divided into 85,10,000 equity shares.
• · Subsidiary's turnover for last 3 years was NIL.
• · Subsidiary incorporated in 2020 in India.
• · Transaction is a related party transaction at arm's length.
• · Consideration is cash.
• · Pre and post allotment shareholding remains 100%.

08-08-2026

Advanced Enzyme Technologies Ltd. reported its Q1 FY27 (quarter ended June 30, 2026) financial results and announced a share buyback of up to ₹697 million (₹69.7 Cr) at a maximum price of ₹500 per share, representing up to 1.24% of equity. The Board also approved acquiring the remaining 4.28% stake in subsidiary JC Biotech Private Limited to make it a wholly owned subsidiary, and approved an additional fund infusion of up to ₹20 million in Advanced Nutrazyme Private Limited. The financial results show consolidated total revenue of ₹1,879.50 million for the quarter, but the filing does not provide prior-period comparative figures for revenue or profit, limiting period-over-period analysis.

• · The Board meeting commenced at 10:00 a.m. and concluded at 11:15 a.m. on August 08, 2026.
• · The buyback will be conducted via the 'Open Market' route through the stock exchange mechanism, excluding promoters and promoter group.
• · The indicative maximum number of shares to be bought back is 1,394,000 equity shares, representing 1.24% of the existing paid-up equity capital.
• · The Maximum Buyback Size of ₹697 million represents 9.99% (standalone) and 5.09% (consolidated) of the aggregate paid-up equity capital and free reserves as on March 31, 2026.
• · Transaction costs (brokerage, taxes, SEBI fees, etc.) are excluded from the Maximum Buyback Size.
• · A Buyback Committee has been constituted to oversee the buyback process.
• · The acquisition of the remaining 4.28% stake in JC Biotech will make it a wholly owned subsidiary (currently 95.72% held).
• · Additional fund infusion of up to ₹20 million in Advanced Nutrazyme Private Limited (wholly owned subsidiary) via equity or inter-corporate deposit.
• · The consolidated results include 13 subsidiaries; four subsidiaries' financials were reviewed by other auditors (total revenue ₹601.80 million, net profit ₹24.90 million for the quarter), and four subsidiaries' financials were not reviewed by auditors (total revenue ₹77.16 million, net profit ₹14.09 million for the quarter).
• · One foreign subsidiary's financials were converted from local GAAP to Ind AS.